Patent: 9,809,648
✉ Email this page to a colleague
Summary for Patent: 9,809,648
Title: | Engineered anti-IL-23p19 antibodies |
Abstract: | Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. |
Inventor(s): | Presta Leonard G., Beyer Brian M., Ingram Richard N., Orth Peter, Liu Yan-Hui |
Assignee: | Merck Sharp & Dohme Corp. |
Application Number: | US13717131 |
Patent Claims: | see list of patent claims |
Details for Patent 9,809,648
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Limited | ILUMYA | tildrakizumab-asmn | Injection | 761067 | March 20, 2018 | ⤷ Sign Up | 2032-12-17 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |